Healthcare -
Biotechnology - NASDAQ - US
$ 13.71
-5.46 %
$ 557 M
Market Cap
-2.75
P/E
INCOME STATEMENT
EFFICIENCY
Earnings Waterfall
Keros Therapeutics, Inc.
| Revenue | 3.55 M |
| Cost Of Revenue | 1.23 M |
| Gross Profit | 2.32 M |
| Operating Expenses | 214 M |
| Operating Income | -211 M |
| Other Expenses | -23.5 M |
| Net Income | -187 M |
Income Statement
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|---|
| REVENUE | |||||||
| Revenue | 3.5 | 0.2 | 0 | 20.1 | 0 | 10.0 | 10.0 |
| GROSS PROFIT | |||||||
| Cost Of Revenue | 1.2 | 0.8 | 1.6 | 0.9 | 0.6 | 17.3 | 10.1 |
| Gross Profit | 2.3 | (0.7) | (1.6) | 19.2 | (0.6) | (7.3) | (0.1) |
| OPERATING INCOME | |||||||
| Operating Expenses | 214.4 | 170.1 | 107.7 | 76.5 | 44.2 | 20.0 | 11.3 |
| Selling, General and Administrative Expenses | 40.8 | 34.8 | 27.5 | 21.3 | 12.8 | 3.2 | 1.6 |
| Research and Development Expenses | 173.6 | 135.3 | 87.3 | 55.1 | 33.9 | 17.4 | 10.1 |
| Operating Income | (210.8) | (169.9) | (114.8) | (56.4) | (46.7) | (10.6) | (1.7) |
| PRE-TAX INCOME | |||||||
| Interest Income Expense | 0 | 0 | 1 K | 4 K | 6 K | 8 K | 0 |
| Total Other Income | 23.8 | 16.9 | 10.1 | (0.4) | 1.1 | (1.8) | 0.6 |
| Pre-Tax Income | (187.1) | (153.0) | (104.7) | (56.7) | (45.5) | (12.3) | (1.1) |
| NET INCOME | |||||||
| Tax Provision | 0.3 | 0 | 1 K | 2.0 | (0.2) | 8 K | 0.3 |
| Net Income | (187.4) | (153.0) | (104.7) | (58.7) | (45.4) | (12.3) | (1.3) |
| EPS | 5 | 5.2 | 4.15 | 2.52 | 2.93 | 1.39 | 0.15 |